PCNA and neoplasm: In SCC-9 tumor cells, AC-AFPK-IsCT1 peptide treatment resulted in a significant decrease in the expression of the proliferation marker PCNA, with a reduction of 21.4 ± 0.4% compared to control cells (Figure 6b).